Irbesartan Accord

Irbesartan, the active ingredient in Irbesartan Accord, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable supply chains and responsive technical support.

Irbesartan is used to manage conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease. - Hypertension: Reduces systolic and diastolic blood pressure, helping to achieve target levels and lower cardiovascular risk. - Diabetic nephropathy: Slows the progression of kidney damage in patients with type 2 diabetes by decreasing intraglomerular pressure.

Irbesartan may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Dizziness: Light‑headed sensation, especially after initial dosing or dose increase. - Headache: Mild to moderate head pain. - Fatigue: General feeling of tiredness. - Hyperkalemia: Elevated blood potassium levels, often asymptomatic. - Nasal congestion: Stuffy nose or sinus discomfort.

Serious or Rare Side Effects: - Angioedema: Swelling of face, lips, tongue, or airway requiring immediate medical attention. - Renal impairment: Sudden decline in kidney function, indicated by rising creatinine. - Hypotension: Marked drop in blood pressure causing faintness or shock. - Hepatic injury: Elevated liver enzymes or jaundice. - Severe hyperkalemia: Potassium >6.5 mmol/L with cardiac arrhythmia risk.

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure safe use. - Renal function: Monitor serum creatinine and eGFR, especially after initiation or dose changes. - Electrolytes: Check potassium levels regularly to detect hyperkalemia. - Concomitant ARBs/ACE inhibitors: Avoid combined use due to increased risk of renal dysfunction and hyperkalemia. - Volume depletion: Caution in patients with dehydration or diuretic therapy to prevent hypotension. - Pregnancy: Discontinue if pregnancy is confirmed, as fetal toxicity is possible. - Store at ambient temperature: Keep below 25 °C in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors: Concurrent use may cause excessive potassium rise and renal impairment. - Potassium‑sparing diuretics or supplements: Increases risk of severe hyperkalemia. - Aliskiren (in diabetics): Combined therapy heightens renal adverse events.

Moderate Interactions (Monitor Closely): - NSAIDs: May reduce antihypertensive effect and impair renal function. - Lithium: May increase lithium levels, risking toxicity. - Cyclosporine or tacrolimus: Can elevate serum creatinine and potassium. - Diuretics: May enhance hypotensive response, requiring dose adjustment.